Availability, prices and affordability of the World Health Organization's essential medicines for children in Guatemala

Globalization and Health

Volumn 8, Issue , 2012, Pages

  Anson, Angela ^a   Ramay, Brooke ^b   de Esparza, Antonio R ^c   Bero, Lisa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD DEL VALLE DE GUATEMALA   (Guatemala)

^c Cedar Associates   (United States)

Author keywords

Availability; Essential medicines for children; Guatemala; National formulary; World Health Organization

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BECLOMETASONE DIPROPIONATE; BENZATHINE PENICILLIN; CARBAMAZEPINE; CEFTRIAXONE; CHLORAMPHENICOL; COTRIMOXAZOLE; DIAZEPAM; FERROUS ASPARTATE; GENTAMICIN; IBUPROFEN; ISONIAZID; MORPHINE SULFATE; ORAL REHYDRATION SOLUTION; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMAQUINE; PROCAINE PENICILLIN; RETINOL; SALBUTAMOL; ZINC; ESSENTIAL DRUG;

CHILD HEALTH; HEALTH POLICY; MEDICINE; PRICE DETERMINATION; PRIVATE SECTOR; PUBLIC SECTOR; WORLD HEALTH ORGANIZATION;

ANEMIA; ARTICLE; ASTHMA; CHILD; CROSS-SECTIONAL STUDY; DEHYDRATION; DRUG COST; GUATEMALA; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH SURVEY; HUMAN; INFECTION; INFLAMMATION; INHALATION SPACER; MALARIA; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PAIN; PRIORITY JOURNAL; SEIZURE; SUSPENSION; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; XEROPHTHALMIA; DEVELOPING COUNTRY; ECONOMICS; HEALTH CARE DELIVERY;

GUATEMALA [CENTRAL AMERICA];

CHILD; DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; GUATEMALA; HEALTH SERVICES ACCESSIBILITY; HUMANS; WORLD HEALTH ORGANIZATION;

EID: 84863094123     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-8-22     Document Type: Article

References (32)

1. World Health Organization Communicable Disease Cluster: Removing obstacles to healthy development: report on infectious diseases http://www.who.int/infectious-disease-report/pages/textonly.html, World Health Organization.
2. United Nations Childrens' Fund The state of the world's children 2008 2007, New York: UNICEF, United Nations Childrens' Fund.
3. The United Nations The millenium development goals report 2010 2010, New York: United Nations, The United Nations.
4. Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, Dwyer L, Costa M, Lopez AD, Murray CJ. Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 2010, 375(9730):1988-2008. 10.1016/S0140-6736(10)60703-9, 20546887.
5. Robertson J, Forte G, Trapsida JM, Hill S. What essential medicines for children are on the shelf?. Bull World Health Organ 2009, 87(3):231-237. 10.2471/BLT.08.053645, 2654638, 19377720.
6. Overview of methods for medicines availability and pricing surveys: Better Medicines for Children Project http://www.who.int/childmedicines/progress/ChildMeds_pricing_surveys.pdf.
7. Health Action International; World Health Organization Meassuring medicine prices, availability, affordability and price components http://www.haiweb.org/medicineprices/manual/documents.html, Health Action International; World Health Organization.
8. Pan American Health Organization Health in the Americas: Guatemala http://www.paho.org/hia/archivosvol2/paisesing/Guatemala%20English.pdf, Pan American Health Organization.
9. Congreso de la República de Guatemala Ley de accesibilidad a los medicamentos 1998, 69-98. Congreso de la República de Guatemala.
10. Congreso de la República de Guatemala Ley de contrataciones del estado 1992, 57-92. Congreso de la República de Guatemala.
11. Shaffer ER, Brenner JE. A trade agreement's impact on access to generic drugs. Health Aff (Millwood) 2009, 28(5):w957-w968.
12. Ventas sociales y farmacias privadas: Ministerio de Salud http://www.mspas.gob.gt/.
13. Jefatura del departamento de regulación y control de productos farmacéuticos y afines 2001, http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40.
14. Jefatura del departamento de regulación y control de productos farmacéuticos y afines 2002, http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40.
15. Jefatura del departamento de regulación y control de productos farmacéuticos y afines 2003, http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40.
16. Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D. Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica 2010, 27(4):291-299. 10.1590/S1020-49892010000400008, 20512232.
17. World Health Organization WHO model list of essential medicines for children: 2nd ed 2009, Geneva, Switzerland: WHO, World Health Organization.
18. OANDA http://www.oanda.com/currency/converter/, OANDA.
19. Management Sciences for Health: International drug price indicator guide http://erc.msh.org/mainpage.cfm?file=1.0.htm&&module=DMP&language=English.
20. Ridge AL, Bero LA, Hill SR. Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res 2010, 10:340. 10.1186/1472-6963-10-340, 3018452, 21162717.
21. Priority Medicines for Maternal and Child Health A Global Survey of National Essential Medicines Lists [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0038055], Priority Medicines for Maternal and Child Health.
22. Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007, 85(4):279-288. 10.2471/BLT.06.033647, 2636320, 17546309.
23. van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010, 10:25. 10.1186/1471-2261-10-25, 2898673, 20534118.
24. Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011, 89(6):412-421. 10.2471/BLT.10.084327, 3099556, 21673857.
25. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009, 373(9659):240-249. 10.1016/S0140-6736(08)61762-6, 19042012.
26. Gwatkin DR, Rutstein S, Johnson K, Suliman E, Wagstaff A, Amouzou A. Socio-economic differences in health, nutrition, and population within developing countries: an overview. Niger J Clin Pract 2007, 10(4):272-282.
27. Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Molbak K, Bhan MK, Sommerfelt H. Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics 2002, 109(5):898-903. 10.1542/peds.109.5.898, 11986453.
28. Goel P, Ross-Degnan D, Berman P, Soumerai S. Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med 1996, 42(8):1155-1161. 10.1016/0277-9536(95)00388-6, 8737433.
29. Worldbank Data by country http://data.worldbank.org/country/guatemala, Worldbank.
30. Niens LM, Cameron A, Van de Poel E, Ewen M, Brouwer WB, Laing R. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010, 7(8):e1000333. 10.1371/journal.pmed.1000333, 2930876, 20824175.
31. World Health Organization WHO model formulary for children. 2010, Geneva, Switzerland: World Health Organization, Retrieved 26 March 2011, from http://www.who.int/selection_medicines/list/WMFc_2010.pdf, World Health Organization.
32. World Health Organization Child growth standards. 2011, Retrieved 26 March, 2011, from http://www.who.int/childgrowth/standards/weight_for_age/en/index.html, World Health Organization.